Home Rx News FDA Approves AstraZeneca’s Durvalumab (Imfinzi) to Treat Advanced Bladder Cancer

FDA Approves AstraZeneca’s Durvalumab (Imfinzi) to Treat Advanced Bladder Cancer

SHARE

The U.S. Food and Drug Administration (FDA) on May 1, 2017, approved the use of AstraZeneca drug Durvalumab (Imfinzi) for the treatment of advanced bladder cancer patients.
The recommended dosage of Durvalumab is 10 mg/kg administered intravenously over 60 minutes every two weeks, and is indicated for treatment in patients with locally advanced or metastic urothelial carcinoma (mUC) with disease progression during or following platinum-containing chemotherapy, or whose disease has progressed within 12 months of receiving platinum-containing chemotherapy. During a single-arm trial of Durvalumab, the drug demonstrated blockage of the PD-L1 protein. PD-L1 is a protein which attaches to the receptors of T cells and inactivates the T cells which would otherwise combat cancer cells in the body.
According to AstraZeneca, AzUrothelial bladder cancer is the ninth most common form of cancer with 430,000 persons diagnosed in 2016 alone with a consequent 165,000 deaths.

Additional information can be obtained at the FDA’s media site and at AstraZeneca’s media site.